A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding
This open-label study (n=10) found a significant increase in mindfulness (MAAS) and openness (NEO PI-R) after a single high dose (14-21mg) of psilocybin.
Authors
- Gitte Knudsen
- Patrick Fisher
- Dea Stenbæk
Published
Abstract
A single dose of the serotonin 2A receptor (5-HT2AR) agonist psilocybin can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness, but underlying mechanisms are unknown. Here, we for the first time conduct a study that assesses psilocybin effects on cerebral 5-HT2AR binding with [11C]Cimbi-36 positron emission tomography (PET) imaging and on personality and mindfulness. Ten healthy and psychedelic-naïve volunteers underwent PET neuroimaging of 5-HT2AR at baseline (BL) and one week (1W) after a single oral dose of psilocybin (0.2-0.3 mg/kg). Personality (NEO PI-R) and mindfulness (MAAS) questionnaires were completed at BL and at three-months follow-up (3M). Paired t-tests revealed statistically significant increases in personality Openness (p-uncorrected = 0.04, mean change [95%CI]: 4.2[0.4;∞]).
Research Summary of 'A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding'
Introduction
Psilocybin, the active compound in ‘‘magic mushrooms’’, is a serotonergic psychedelic whose active metabolite psilocin stimulates cortical serotonin 2A receptors (5-HT2AR) and produces a transient altered state of consciousness. Previous clinical and experimental studies have reported that a single dose of psilocybin can yield persistent improvements in mood, reductions in depressive and anxiety symptoms, and long-term increases in the personality trait Openness. Reports and small studies have also suggested that mindfulness-related capacities may increase after psychedelic use, but the durability of such changes and their neurobiological substrates remain unclear. Preclinical work and cross-sectional PET data further suggest that 5-HT2AR agonists can induce receptor internalisation or down-regulation, making changes in cerebral 5-HT2AR levels a plausible molecular mechanism for long-term psychological effects. Korsbak Madsen and colleagues set out to evaluate, in healthy psychedelic-naïve volunteers, whether a single oral dose of psilocybin alters cerebral 5-HT2AR binding and whether any early receptor changes predict longer-term changes in personality and mindfulness. To do so, the investigators obtained [11C]Cimbi-36 PET scans before and one week after psilocybin, and assessed personality and trait mindfulness at baseline and at three months, testing the a priori hypothesis that the trait Openness would increase and exploring associations between receptor-level changes and later psychological outcomes. This approach aims to link molecular neuroimaging with persistent psychological effects following a single psychedelic exposure.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., & Knudsen, G. M. (2020). A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology, 33, 71-80. https://doi.org/10.1016/j.euroneuro.2020.02.001
References (27)
Papers cited by this study that are also in Blossom
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E. et al. · Psychopharmacology (1999)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Show all 27 referencesShow fewer
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Stenbæk, D. S., Kristiansen, S., Burmester, D. et al. · Human Brain Mapping (2019)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Cited By (66)
Papers in Blossom that reference this study
Cherniak, A. D., Granqvist, P., Mikulincer, M. et al. · Journal of Psychoactive Drugs (2026)
Kirlić, N., Atli, M., Mistry, S. et al. · Journal of Clinical Psychopharmacology (2025)
Murphy, R. J., Wardlaw, M., Smith, T. et al. · Journal of Humanistic Psychology (2025)
Johansen, A., Plavén-Sigray, P., Madsen, M. K. et al. · Research Square (2025)
McCulloch, D. E-W., Larsen, K., Johansen, A. et al. · MedRvix (2025)
Fink-Jensen, A., Jensen, M. E., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2025)
Larsen, K., Lindberg, U., Ozenne, B. et al. · Journal of Cerebral Blood Flow and Metabolism (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Kirlic, N., Lennard-Jones, M., Atli, M. et al. · American Journal of Psychiatry (2025)
Pagni, B. A., Zeifman, R. J., Mennenga, S. E. et al. · American Journal of Psychiatry (2025)
Show all 66 papersShow fewer
Agnorelli, C., Spriggs, M. J., Godfrey, K. et al. · Preprints (2024)
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H. et al. · Journal of the Neurological Sciences (2024)
Sloshower, J. A., Zeifman, R. J., Guss, J. et al. · Scientific Reports (2024)
Orłowski, P., Hobot, J., Ruban, A. et al. · Psychophysiology (2024)
Erritzoe, D., Barba, T., Spriggs, M. J. et al. · Journal of Psychopharmacology (2024)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Humanistic Psychology (2024)
Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)
Barba, T., Kettne, H., Radu, C. et al. · Scientific Reports (2024)
Madsen, M. K., Petersen, A. S., Stenbæk, D. S. et al. · Headache (2024)
Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)
Wall, M. B., Harding, R., Zafar, R. et al. · Molecular Psychiatry (2023)
Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)
Mortaheb, S., Fort, L. D., Mason, N. L. et al. · Biological Psychiatry (2023)
Neubert, J. J., Anderson, K., Mason, N. L. · Psyarxiv (2023)
Pizzi, S. D., Chiacchiaretta, P., Sestieri, C. et al. · Biological Psychiatry (2023)
Weiss, B., Ginige, I., Shannon, L. et al. · Psychological Medicine (2023)
Azmoodeh, K., Thomas, E., Kamboj, S. K. · Experimental and Clinical Psychopharmacology (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Burmester, D., Madsen, M. K., Szabo, A. et al. · Comprehensive Psychoneuroendocrinology (2023)
Modlin, N. L., Miller, T. M., Rucker, J. J. et al. · Journal of Affective Disorders (2023)
Lutkajtis, A., Evans, J. · Journal of Psychedelic Studies (2023)
DellaCrosse, M., Pleet, M. M., Morton, E. et al. · PLOS ONE (2022)
Olsen, A. S., Ozenne, B., Madsen, M. K. et al. · NeuroImage (2022)
Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)
Madsen, M. K., Ozenne, B., Armand, S. et al. · Frontiers in Psychology (2022)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Radakovic, C., Radakovic, R., Peryer, G. et al. · Journal of Psychedelic Studies (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)
Johnson, S., Letheby, C. · Journal of Psychedelic Studies (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Smedfors, G., Glotfelty, E., Papatziamos, C. et al. · Research Square (2022)
Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)
Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L. et al. · Frontiers in Psychology (2021)
Strumila, R., Guillaume, S. · Pharmaceuticals (2021)
Garcia-Romeu, A., Darcy, S., Jackson, H. et al. · Current Topics in Behavioral Neurosciences (2021)
Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)
Letheby, C. · Psyarxiv (2021)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Hirschfeld, T., Schmidt, T. T. · Journal of Psychopharmacology (2021)
Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M. et al. · Journal of Psychopharmacology (2021)
McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)
Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)
Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Stenbæk, D. S., Madsen, M. K., Ozenne, B. et al. · Journal of Psychopharmacology (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.